A

Amgen

Makes biotech medicines for serious illnesses

Director Commercial Analytics - Obesity

Full-TimeUpdated on 10/24/2026
No salary listed
Expert
Bachelor's, Master's, PhD
Hyderabad, Telangana, India
In Person
Business & StrategyBusiness Operations

About the job

Requirements
  • A doctorate degree, a master's degree, or a bachelor's degree with 18 or more years of relevant experience is required.
  • Substantial experience in commercial analytics, strategic insights, consulting, or related functions within pharmaceuticals, biotechnology, healthcare, or life sciences is preferred.
  • Depth across product and brand strategy, launch analytics, sales force effectiveness, HCP and account analytics, payer and pricing analysis, commercial measurement, and executive insight translation is preferred.
  • Experience supporting U.S. or global launches and growth assets in competitive, rapidly evolving therapeutic categories, ideally with high access and execution complexity, is preferred.
  • Strong understanding of U.S. pharmaceutical commercialization, selling models, field execution, stakeholder prioritization, and healthcare ecosystem dynamics is preferred.
  • Knowledge of U.S. healthcare data ecosystems used for commercial decision-making, including sales, field activity, promotional engagement, claims, payer and pricing, and access-related data, is preferred.
  • Proven ability to translate complex analysis into recommendations that influence senior stakeholders and action planning is preferred.
  • Experience partnering with technology, data science, and data engineering teams to develop scalable analytics products is preferred.
  • Strong executive communication, stakeholder management, strategic thinking, and ability to balance practical delivery with high-quality analytical standards in a global environment are preferred.
Responsibilities
  • Set the commercial analytics agenda for obesity, including the roadmap, delivery priorities, and senior decision forums.
  • Turn product, field, account, payer and pricing, and U.S. stakeholder questions into pragmatic analytical plans and usable decision assets.
  • Manage intake, prioritization, quality, governance, and execution without unnecessary process burden.
  • Surface risks, options, and trade-offs early, supported by evidence and grounded in commercial reality.
  • Raise standards for reusable methods, evolve how the function works, and build capabilities that improve over time as business needs change.
  • Shape analysis that informs product strategy, commercialization readiness, lifecycle planning, and in-market action.
  • Track the competitive landscape, treatment environment, access and pricing shifts, HCP behavior, and external signals, with strong attention to U.S. dynamics.
  • Synthesize market, customer, competitive, and policy insights into assessments of launch readiness.
  • Synthesize internal and external data to identify opportunities, risks, and strategic priorities, and convert them into executive-ready narratives that clarify implications and decisions.
  • Lead analysis for field sizing, customer segmentation, HCP and account engagement, and field execution.
  • Develop national and sub-national insights that guide resource allocation, launch sequencing, and customer prioritization.
  • Work across commercial, medical, market access, and product teams to evaluate strategic options and inform planning.
  • Advance patient journey, market landscape, and stakeholder insights to inform priorities.
  • Develop executive-ready insights that anticipate risks, highlight opportunities, and enable confident choices.
  • Develop predictive models, scenario simulations, segmentation approaches, and driver analyses to answer high-value business questions.
  • Apply quantitative techniques to estimate demand, assess adoption drivers, and evaluate the impact of market and competitive changes.
  • Industrialize analytical methods through scalable, governed, and reusable solutions in partnership with data science and technology teams.
  • Establish analytical standards, validation practices, and documentation that improve consistency, transparency, and confidence in outputs.
  • Expand the use of automation, artificial intelligence, and experimentation to accelerate delivery and increase analytical rigor.
  • Own the commercial analytics operating model for domain intake, prioritization, standards, delivery cadence, quality, and adoption.
  • Standardize recurring work into reusable insight products, tools, and methods where scale creates value.
  • Clarify how the function partners with forecasting, primary market research, and technology colleagues to deliver integrated work.
  • Improve speed, consistency, and impact through pragmatic reuse, automation, and fit-for-purpose solutions.
  • Build a connected capability recognized by the global obesity business for judgment, reliability, and business partnership.
  • Build, develop, and lead a high-performing India-based team of analytics professionals.
  • Create an environment of analytical excellence, accountability, curiosity, continuous learning, and ownership.
  • Coach future leaders by expanding their commercial judgment, technical depth, strategic thinking, executive communication, and ability to influence across a global organization.
  • Set clear goals, performance expectations, and development paths that link individual growth to organizational priorities.
  • Help the team understand the business behind the analysis while creating an environment where curiosity, ownership, and continuous learning are expected and rewarded.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.